
FOLFIRINOX Chemotherapy
Four old drugs given together every two weeks, with a pump that runs for two days at home. After pancreatic cancer surgery that routine added a year and a half of median survival over gemcitabine, and it asks a lot of the patient in return. This guide covers the trials, the side effects, who is fit for it and how a course is shared between Istanbul and home.
About This Department
After pancreatic cancer surgery, six months of FOLFIRINOX raised median survival from 35 to 54 months. FOLFIRINOX also ranks among the hardest chemotherapy regimens to get through.
FOLFIRINOX combines four old drugs, fluorouracil, leucovorin, irinotecan and oxaliplatin, every two weeks, with a portable pump that runs for two days at home. In the trial that introduced it, patients with metastatic pancreatic cancer lived a median of 11.1 months against 6.8 with gemcitabine, and their quality of life held up longer despite the harder regimen. It suits fit patients, and fitness is the first thing to assess. Send us your pathology, scans and blood tests, and a medical oncologist will tell you whether the full regimen, a modified one or a gentler alternative fits you.
What is FOLFIRINOX?
The name spells out its contents. FOL for folinic acid, also called leucovorin. F for fluorouracil. IRIN for irinotecan. OX for oxaliplatin. Each of the four had been used for decades on its own or in pairs, in bowel and stomach cancer, when a French group put all four together in the 2000s for pancreatic cancer, a disease against which chemotherapy had achieved very little, with the standard drug of the time, gemcitabine, adding weeks and not months to survival and shrinking the tumor in fewer than one patient in ten. The combination attacks cancer cells in three different ways at once. That makes it work. It also makes it hard.
As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.Conroy and colleagues, New England Journal of Medicine, 2011
The four drugs, one by one
Oxaliplatin, a platinum drug, damages DNA and is given as a two-hour drip. Its signature side effect is nerve damage, first as tingling in the fingers and mouth brought on by cold, later as numbness that can last.
Irinotecan blocks an enzyme that cancer cells need to copy their DNA, and it runs for 90 minutes. Diarrhea is its mark.
Leucovorin is a vitamin that makes fluorouracil work harder, given over two hours alongside irinotecan. Fluorouracil itself blocks the building blocks of DNA and runs through a small portable pump for 46 hours at home. A port under the skin is therefore needed before the first cycle.
Where is it used?
Pancreatic cancer in three situations
After surgery. Six months of a modified FOLFIRINOX is the standard for fit patients whose pancreatic cancer has been removed, since the PRODIGE 24 trial described below.
Before surgery or in place of it. When the tumor wraps around the major vessels and cannot be removed at diagnosis, FOLFIRINOX is given first, sometimes followed by radiotherapy, and a quarter of patients in the pooled studies were able to have an operation afterward.
In metastatic disease. For fit patients it is one of the two first-line standards, alongside gemcitabine with nab-paclitaxel, and a related regimen called NALIRIFOX has joined them.
Bowel cancer uses it too.
The same four drugs, in slightly different doses and called FOLFOXIRI, are used in metastatic bowel cancer for fit patients whose liver metastases might become removable, and in some stomach and bile duct cancers.
What did the trials find?
How to read the table
Two of the trials compared FOLFIRINOX with gemcitabine, the drug it replaced, in patients who all had the same disease and were randomly assigned. Those are the strongest evidence. The meta-analysis for locally advanced disease pooled studies without a comparison group, and the authors themselves asked for a randomized trial to confirm it.
Fitness was an entry ticket. Every trial in the table enrolled patients able to look after themselves and spend most of the day out of bed. The results do not carry over to patients who are frail, jaundiced or severely weakened.
This table scrolls sideways on a narrow screen. Swipe or drag to see every column.
| Setting | Trial | Compared | Result | Toxicity |
|---|---|---|---|---|
| Metastatic pancreatic cancer | PRODIGE 4, 342 patients, New England Journal of Medicine 2011 | FOLFIRINOX against gemcitabine | Median survival 11.1 against 6.8 months. Response 31.6 against 9.4 percent. Quality of life held longer | More adverse events. Febrile neutropenia 5.4 percent |
| After surgery for pancreatic cancer | PRODIGE 24, 493 patients, New England Journal of Medicine 2018 | Modified FOLFIRINOX against gemcitabine for 24 weeks | Median survival 54.4 against 35.0 months. Alive at three years 63.4 against 48.6 percent | Grade 3 or 4 events 75.9 against 52.9 percent |
| Locally advanced pancreatic cancer | Meta-analysis of 13 studies, 689 patients, Lancet Oncology 2016 | No comparison group | Median survival 24.2 months. Resection afterward in 25.9 percent, with clear margins in 78 percent of those | 60 serious events per 100 patients. No deaths from toxicity |
| Metastatic pancreatic cancer | NAPOLI 3, 770 patients, Lancet 2023 | NALIRIFOX against gemcitabine with nab-paclitaxel | Median survival 11.1 against 9.2 months | Grade 3 or worse 87 against 86 percent |
| Metastatic bowel cancer | GONO, 244 patients, Journal of Clinical Oncology 2007 | FOLFOXIRI against FOLFIRI | Response 66 against 41 percent. Median survival 22.6 against 16.7 months. Liver metastases removed in 36 against 12 percent | Nerve damage 19 against 0 percent. Severe neutropenia 50 against 28 percent |
What does a cycle involve, and what are the side effects?
- Day one, morning. Blood count, kidney and liver tests, a check of weight and symptoms. Anti-sickness drugs and atropine, which prevents the early diarrhea irinotecan causes.
- Day one, in the day unit. Oxaliplatin over two hours, then irinotecan with leucovorin over 90 minutes to two hours. Four to five hours in all.
- Day one, afternoon. The fluorouracil pump is connected to the port, a small bottle carried in a pouch. You go home or to the hotel with it.
- Day three. The pump is disconnected, at the hospital or by a home nurse. An injection of growth factor to protect the white cells is given in many units.
- Days four to fourteen. Recovery, with the low point of the blood count between day eight and day twelve, when infection is most dangerous and crowds, sick visitors and raw food are best avoided.
- Tiredness, the most common complaint, heaviest in the first week of each cycle.
- Nausea, controlled in most patients by the tablets sent home.
- Diarrhea, from irinotecan, treated at the first loose stool with loperamide on a schedule the nurse explains.
- Tingling and cold sensitivity in the hands, feet and mouth, from oxaliplatin. Avoid cold drinks for a few days.
- Low white cells in the second week, the side effect that turns a fever into an emergency and the reason a growth-factor injection is given after each pump in many units.
- Hair thinning, mouth soreness and loss of appetite.
- A temperature of 38 degrees or more, or shivering, at any time.
- Diarrhea more than four times a day despite loperamide, or any diarrhea with fever.
- Vomiting that stops you drinking.
- Chest pain, breathlessness, or a painful swollen arm on the side of the port.
- A pump that alarms, leaks or has stopped.
This table scrolls sideways on a narrow screen. Swipe or drag to see every column.
| Problem | Trial | Frequency |
|---|---|---|
| Fever with low white cells | Metastatic pancreatic cancer, PRODIGE 4 | 5.4 percent |
| Any grade 3 or 4 event | After surgery, PRODIGE 24, modified regimen | 75.9 percent, against 52.9 with gemcitabine |
| Grade 3 or 4 events per 100 patients | Locally advanced disease, meta-analysis | 60.4 |
| Nerve damage, grade 2 or 3 | Bowel cancer, FOLFOXIRI | 19 percent |
| Severe neutropenia | Bowel cancer, FOLFOXIRI | 50 percent |
Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects.PRODIGE 24, New England Journal of Medicine, 2018
Who should not receive full FOLFIRINOX
Patients who spend much of the day in bed, patients over 75 with other illnesses, and patients with a bilirubin above one and a half times normal were excluded from the trials, and they do worse on the regimen. Jaundice must be relieved with a bile duct stent first. For them, gemcitabine with nab-paclitaxel, gemcitabine alone or a gentler doublet is the better choice.
Two blood tests come first. A DPD test looks for a deficiency of the enzyme that breaks down fluorouracil, which can make a normal dose dangerous, and European regulators have recommended it before fluorouracil since 2020. A UGT1A1 test shows who clears irinotecan slowly. Either result leads to a lower dose, and treatment goes ahead.
Days in Istanbul, and how a course is shared with home
Twelve cycles over six months make a full course. Few patients spend that abroad. The usual plan is one to two weeks here, and that is the length of stay the majority need. That covers the consultation and staging, the DPD test, the tumor board, port placement as a day procedure, the first cycle with its pump, and a review in the second week when the blood count is at its lowest. The regimen and the doses are then written up for your own oncologist, and the remaining cycles are given at home, where the drugs are widely available and cheap.
Surgery changes the calendar. The operation and recovery take two to three weeks, and chemotherapy after it begins eight to twelve weeks later, at home or here, once the wound has healed and the patient is eating well enough to withstand six months of treatment. Flying is safe once the pump is off and the blood count has recovered, which means avoiding days eight to twelve of a cycle.
What decides the cost
The four drugs are old and generic, so the medicines themselves are a modest share of the bill. The day-unit time, the pump and its disposables, the growth-factor injections, the anti-sickness drugs and the blood tests before each cycle make up the rest, the port placement is a one-off procedure paid once at the start, and because the whole regimen is off patent the gap between a careful quote and a careless one lies almost entirely in these supporting items. The chemotherapy itself is cheap. An admission for fever or diarrhea is the largest unknown, and a quote should include a daily rate for it.
Packages published by hospitals in Istanbul for pancreatic cancer chemotherapy quote a course of four cycles over about two months and describe FOLFIRINOX as costing a fifth to a third more than gemcitabine. Ask what the figure contains. Growth factor, pump and port matter most. Your own figure follows the free review of your file.
Language, companions and follow-up at home
One coordinator from the international patients team is assigned from your first message and stays with you through the visit. The team works in English, Arabic, French, Russian, Serbian, Romanian and Spanish and arranges interpreting in other languages on request. An invitation letter naming the hospital and the treating oncologist is sent ten days before travel. The international patients office arranges the airport transfer and a hotel near the hospital for you and a companion, and a companion is needed during the first cycle. Rooms for admitted patients have a companion bed. Halal, vegetarian and diabetic meals are available, a prayer room is on site, and a request for a female doctor is passed to the department and met wherever the rota allows. Back home, the coordinator stays reachable on the same WhatsApp number, and the oncologist here reviews your blood tests and scans on request. Surgery, radiotherapy and medical oncology share one site, so a tumor board that recommends surgery after FOLFIRINOX can schedule it without a change of hospital.
FOLFIRINOX FAQ
What does FOLFIRINOX stand for?
How effective is FOLFIRINOX for pancreatic cancer?
How many cycles are given?
What are the main side effects?
Can I have the treatment at home after starting it in Istanbul?
Can my family come with me?
Our findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of metastatic pancreatic ductal adenocarcinoma.NAPOLI 3, The Lancet, 2023
References
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine. 2011;364(19):1817-1825.
- Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine. 2018;379(25):2395-2406.
- Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology. 2016;17(6):801-810.
- Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272-1281.
- Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer. Journal of Clinical Oncology. 2007;25(13):1670-1676.
Editor's note
Written by the Biruni Hospital medical editorial team. Reviewed by Prof. Dr. Özcan YILDIZ, Medical Oncology.
Medically reviewed by

Prof. Dr. Özcan YILDIZ
Medical Oncology
Related Treatments
View All
ALK Inhibitor Therapy
ALK inhibitor therapy treats ALK-positive lung cancer with a daily tablet taken at home. In the CROWN trial 60 percent of patients on lorlatinib were free of progression at five years, alectinib cut brain progression from 45 to 12 percent in ALEX, and two years of alectinib after surgery now protects early disease.

Anti-Angiogenic Therapy
Anti-angiogenic therapy blocks VEGF, the signal tumors use to grow their own blood vessels. Bevacizumab is given by drip with chemotherapy or immunotherapy, and tablets such as sunitinib, axitinib, cabozantinib and lenvatinib are taken at home. It treats bowel, liver, kidney, ovarian, cervical, lung and thyroid cancers. Our oncologists check blood pressure, bleeding risk and surgery timing before the first dose and follow you once you are back home.

Antibody Drug Conjugate Therapy - ADC Therapy
An antibody drug conjugate links an antibody that finds cancer cells to a powerful chemotherapy drug, delivering it inside the tumor. ADCs are now standard in HER2-positive, HER2-low and triple-negative breast cancer and in advanced bladder cancer, where enfortumab vedotin with pembrolizumab raised median survival from 16.1 to 31.5 months.

Atezolizumab Therapy - Tecentriq
Atezolizumab is an immunotherapy drip that blocks PD-L1, the protein tumors use to switch off the immune cells attacking them. It is approved for lung cancer after surgery and in advanced disease, for small cell lung cancer and, with bevacizumab, for advanced liver cancer, where it raised one-year survival from 54.6 to 67.2 percent.

Bevacizumab Therapy - Avastin
Starving a tumor of new blood vessels sounds as if it should work everywhere. The trials say otherwise. Bevacizumab added months of life in bowel, lung, cervical and liver cancer, delayed ovarian cancer, and did nothing for survival in newly diagnosed glioblastoma. This guide gives each result, the side effects, the biosimilars and how a course is planned.